4
Changes in Ownership
Seres Therapeutics, Inc. Filed Acc 0001209191-15-057217
CTO and EVP of Bioprocess Dev. acquired 34,090 shares (conversion)
From the SEC's structured data for this filing
Trades in this filing
Aunins John G. · CTO and EVP of Bioprocess Dev.
Table I: Non-derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2015-06-26 | Conversion : show line 1 in the form | +34,090 | 84,090 | D |
Table II: Derivative
2 lines| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2015-06-26 | Conversion : show line 2 in the form Series B Convertible Preferred Stock | −34,090 | 34,090 | 0 | D | ||
| 2015-06-25 | Grant or award : show line 3 in the form Stock Option (right to buy) | +50,000 | $18.00 | 2025-06-24 | 50,000 | 50,000 | D |
Loading xslF345X03/doc4.xml…